Trial Profile
An Open-label Extension Study of Ralinepag in Patients With Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Ralinepag (Primary) ; Ralinepag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Arena Pharmaceuticals; United Therapeutics Corporation
- 10 Jan 2024 Results of long-term safety and tolerability, efficacy, published in the Advances in Therapy
- 29 Apr 2022 According to an United Therapeutics Corporation Media Release, long term data from this study will be presented at the 2022 American Thoracic Society (ATS) International Conference.
- 01 Jul 2021 Status changed from active, no longer recruiting to completed.